IBM and Nvidia move quantum processors into supercomputing workflows
New Slurm integration, a Fermilab co-design platform and GPU-accelerated error-correction tools aim to make quantum processors usable inside established HPC environments.
Quantum / NEWS BRIEF
The all-stock deal adds an established Zero Trust network-security platform to IonQ's post-quantum cryptography and quantum-key-distribution portfolio.
IonQ announced on Nov. 4 that it had completed its acquisition of Zero Trust security company Elisity. IonQ's SEC filing records the legal closing on Nov. 3 and says it issued 32,233,274 common shares at closing. The company valued that consideration at $1.15 billion; sellers can receive up to another $150 million tied to revenue milestones through January 2028. Independent reporting confirmed the disclosed transaction terms.
Elisity's software discovers connected assets, evaluates network risk and applies identity-based Zero Trust policies. IonQ plans to combine that platform with its post-quantum cryptography and quantum key distribution products, while keeping Elisity under its current leadership and maintaining existing deployments. IonQ says Elisity has more than 100 enterprise deployments; that customer count is company-reported rather than independently audited.
The deal is consequential because a quantum-computing company is spending heavily to assemble a broader security stack that can be sold before fault-tolerant quantum computers arrive. Elisity's present-day Zero Trust business may also give IonQ established enterprise relationships for future cryptographic products. The acquisition does not demonstrate better qubits, stronger quantum-key-distribution performance or proven integration benefits; those remain commercial claims to test after the companies combine their products.
New Slurm integration, a Fermilab co-design platform and GPU-accelerated error-correction tools aim to make quantum processors usable inside established HPC environments.
OpenAI has released healthcare-focused computer-use capabilities across its API and clinical products, with configurable approvals, audit logs and new performance results that remain provider-reported.